Article
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.
Nature communications - 25 Apr 2026
Choo Joan, Zhao Joseph J, Lau Mai Chan, Raimondi Alessandra, Yim Willa Wen-You, Ranganathan Sruthi, Zhu Kexin, Tan Crystal Tze Ying, Chin Hui Xian, Teo Chong Boon, Fong Khi Yung, Tay Ryan Yong Kiat, Lee Jia-Ying Joey, Loo Lit-Hsin, Manca Paolo, Morano Federica, Prisciandaro Michele, Randon Giovanni, Damonte Camilla, Micarelli Elisa, Leoni Guido, Scarselli Elisa, Lonardi Sara, Cremolini Chiara, Marmorino Federica, Lim Jeffrey Chun Tatt, Neo Zhen Wei, Wee Felicia, Chong Li Yen, Joseph Craig Ryan, Balachander Akhila, Lim Diana Gs, Hwang You Yi, Renia Laurent, Biswas Subhra Kumar, Tan David, Yeong Joe P S, Sundar Raghav, Pietrantonio Filippo
Abstract excerpt
Microsatellite-stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI). The MAYA trial used temozolomide (TMZ) in MGMT-silenced MSS mCRC, hypothesizing that TMZ-induced hypermutation could sensitize tumors to ICI; the primary endpoint was met, showing durable responses with TMZ plus ipilimumab and nivolumab. We perform integrated spatial, transcriptomic, and immune...
Topics
Join the communities discussing this publication.